WS
SLS icon

Wedbush Securities’s SELLAS Life Sciences SLS Stock Holding History

Wedbush Securities’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,000
Closed -$18K – 1231
2024
Q2 		$18K Buy
+15,000
New +$20.4K ﹤0.01% 1191
2019
Q1 		– Sell
-202
Closed -$12K – 949
2018
Q4 		$12K Buy
+202
New +$15.6K ﹤0.01% 821

Other funds holding SLS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Wedbush Securities's SLS Position: Q3 2024 in Review

Wedbush Securities sold out of SELLAS Life Sciences (SLS) in Q3 2024, closing a stake of 15,000 shares — an estimated $18K sold.

Wedbush Securities first reported a position in SLS in Q4 2018 and held it in 2 quarters. The position peaked at $18K in Q2 2024. 33 funds tracked by Wall St. Rank hold SLS as of Q3 2024.

  • Wedbush Securities reported no remaining SELLAS Life Sciences position as of Q3 2024 after selling out during the quarter.
  • Wedbush Securities sold 15,000 SELLAS Life Sciences shares in Q3 2024, an estimated $18K.
  • Wedbush Securities first reported a position in SELLAS Life Sciences in Q4 2018 and held it in 2 quarters.
  • Wedbush Securities's SELLAS Life Sciences position peaked at $18K in Q2 2024.
  • 33 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q3 2024.

Based on Wedbush Securities's 13F filing for Q3 2024, filed 8 Nov 2024.